Anupam Rasayan to buy 74.2% Bliss GVS at ₹299 (2026)

Board clears control acquisition of Bliss GVS Pharma

Anupam Rasayan India Limited said its board has approved the acquisition of up to 74.20% equity shares and control of Bliss GVS Pharma Limited. The proposed transaction is priced at ₹299 per share, based on the information shared. The structure includes a share purchase agreement to buy a 43.30% stake, alongside an open offer for 26%. The development marks a clear shift from earlier market chatter, with the company now moving to a board-approved plan. The update was accompanied by other board-level decisions, including auditor-related items and a senior finance resignation. The company operates in the Chemicals and Petrochemicals sector under the Chemicals sub-classification. Its BSE code is 543275.

Deal structure: SPA plus open offer

The disclosed plan outlines two main legs of acquisition. First is a share purchase agreement that covers a 43.30% stake in Bliss GVS Pharma. Second is an open offer for an additional 26% stake, which together take the potential holding to 74.20%. The disclosure explicitly describes the outcome as acquisition of “equity shares and control,” indicating the transaction is designed to deliver controlling rights if completed as proposed. The reported price for the acquisition is ₹299 per share. Beyond these headline terms, no additional conditions, timelines, or regulatory milestones were specified in the provided text. Investors typically track whether such a transaction progresses through detailed exchange filings and open offer documentation.

Bliss GVS Pharma’s reported turnover figure

The target company, Bliss GVS Pharma Limited, reported a turnover of ₹1,000.64 crore for FY 2025-2026, as stated in the deal-related update. This figure provides a snapshot of scale, although the text does not provide profitability, margin, or balance-sheet details. The turnover number is presented as a single-year metric and there is no comparative history in the supplied material. The data point becomes relevant because it is one of the few disclosed financial indicators about the target alongside the acquisition price per share. The announcement does not describe how the acquirer values the business or the strategic rationale. It also does not specify whether Bliss GVS has any segmental exposure that directly overlaps with Anupam Rasayan’s specialties.

Corporate actions: auditors and Deputy CFO resignation

Alongside the acquisition approval, the board deliberated on the re-appointment of statutory auditors and cost auditors. The company also accepted the resignation of Mr. Vishal Thakkar from the post of Deputy Chief Financial Officer. The information shared does not detail the effective date or reasons for the resignation. It also does not name successors or interim arrangements for the finance function. Such corporate governance items often draw attention because they can influence reporting continuity and internal controls, especially around major transactions. However, based on the provided text, only the acceptance of resignation and the auditor re-appointment deliberation are confirmed.

CRISIL action: ‘Rating Watch Negative’ removed

CRISIL Ratings removed Anupam Rasayan India from ‘Rating Watch Negative’ and reaffirmed A+/Stable ratings on ₹1,369.82 crore facilities, according to the supplied update. The stated driver for this rating action was the company’s successful funding of a US$150 million acquisition. The funding mix described includes US$11 million of debt and US$109 million of equity from Oaktree Capital. The text does not provide the specific instruments, maturity profile, or covenants linked to the debt portion. It also does not specify whether the reaffirmed ratings apply to specific bank lines, term loans, or other facilities, beyond the aggregate facility size.

Jayhawk Fine Chemicals acquisition: funding context

Separately, the material notes that Anupam Rasayan India Ltd. acquired 100% equity stake in Jayhawk Fine Chemicals Corporation for approximately US$150 million. The CRISIL reference links its rating action to the successful funding of this US$150 million acquisition, describing US$11 million debt and US$109 million equity support from Oaktree Capital. This context matters because it indicates the company has recently executed a large overseas deal and arranged financing to complete it. The update does not indicate whether the Bliss GVS transaction will require additional financing or how it will be funded. It also does not specify whether the Bliss acquisition will run in parallel with integration work related to Jayhawk. Readers should therefore treat the two items as distinct disclosures connected mainly through timing and the rating narrative.

Earlier denials: February 13, 2026 clarification on speculation

The provided text also includes an earlier episode tied to the same target. On February 13, 2026, Anupam Rasayan India Ltd. issued a formal clarification in response to media reports suggesting it planned to acquire a stake in Bliss GVS Pharma Ltd. The company stated that no such material event or information existed that warranted disclosure under regulatory requirements and said it did not wish to comment on speculation. The note also reiterated compliance with disclosure norms, including SEBI LODR regulations referenced in the text. This historical context is notable because it shows the company previously rejected the idea as a disclosure-triggering event, while the latest update describes a board-approved acquisition proposal. The supplied material does not explain what changed between the clarification and the board’s decision.

Stock and sector context mentioned in the update

The dataset includes market reference points for Anupam Rasayan’s stock. The last close price is listed as ₹1,343.30, and an “average target price” is noted as ₹976.43. The source and timeframe for the target price are not provided in the text. The company is described as being engaged in custom synthesis (CSM) and manufacturing of specialty chemicals. It operates through Life Science related Specialty Chemicals and Other Specialty Chemicals segments, serving agrochemicals, personal care, pharmaceuticals, and other specialty chemical applications. While this business profile helps frame investor perception, the disclosure does not link these segments directly to Bliss GVS or specify how the acquisition will be integrated operationally.

Key facts table

Why the development matters for investors

The board approval provides a concrete transaction framework after a period in which the company had publicly denied that any disclosure-worthy event existed around Bliss GVS. For investors, the most material disclosed levers are the stake size, the control intent, and the ₹299 per share price. The only disclosed financial metric for the target in the supplied text is turnover of ₹1,000.64 crore for FY 2025-2026, which can help readers gauge the target’s scale but not profitability. The CRISIL update adds another layer by indicating improved credit visibility after funding the US$150 million Jayhawk acquisition, with A+/Stable reaffirmed on ₹1,369.82 crore facilities. At the same time, the acceptance of a Deputy CFO resignation is a governance item worth monitoring for continuity, though no further details are provided. The next set of clarity points, based strictly on what is shared, would likely come through formal transaction documents and subsequent exchange disclosures.

Conclusion

Anupam Rasayan’s board has approved a plan to acquire up to 74.20% and control of Bliss GVS Pharma at ₹299 per share, via a 43.30% share purchase agreement and a 26% open offer. The update also covers auditor re-appointment deliberations and the resignation of Deputy CFO Mr. Vishal Thakkar. Separately, CRISIL removed the company from ‘Rating Watch Negative’ and reaffirmed A+/Stable on ₹1,369.82 crore facilities following successful funding for the US$150 million Jayhawk acquisition. Market participants will now watch for detailed filings that set out transaction terms, open offer process steps, and any further regulatory updates.